Balance sheetWarning
부채총계 급증 (+429%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Corvus Pharmaceuticals
CRVS-US · Nasdaq$14.09-2.56%
2026-08-24 closeCorvus Pharmaceuticals — pricey right now, or cheap? And what signals are flashing today?
The grade and valuation bands are below — free to read.
Loading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
New high + volume — the real recordrecord · not a prediction
Not this one stock, but every new-high-plus-volume pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)
Last 30 sessions
257 picks
Next-day win rate
41%
Avg next-day
-0.41%
vs market
-0.58%p
Beat the market on 40.6% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
08-21 42.9%08-20 57.1%08-19 11.1%08-18 75%08-17 50%08-14 66.7%08-13 16.7%08-12 25%08-11 45.5%08-10 23.1%08-07 54.5%08-06 46.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Trade plan
Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.
Valuation Grades
Relative to 752 건강관리 peers · not investment advice
A-
Overall: 건강관리 159/752 · top 21%
Factor composite · relative position in sector
Valuation in its own history
PER — · PBR 32.31 — own history (2016-03~) percentiles 93/100 · 0/100
PER93/100
PBR0/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -18.72
Distress
Grey
Safe
- Altman Z''
- -18.72
- Beneish M-Score
- —
- Sloan accrual
- -53.51%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
1/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score1/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Margin trendWarning
영업외손익 급변 (영업이익 대비 113% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Financials at a glance
Corvus Pharmaceuticals's latest results and balance sheet. The bars track the last three periods.
Connections
AI-extracted related companies · for reference
Competitors
IncytePrice comovement r=0.17 (1 year)MerckPrice comovement r=0.10 (1 year)Bristol Myers SquibbPrice comovement r=0.14 (1 year)RocheNovartisPfizerPrice comovement r=0.17 (1 year)AstraZenecaAmgenPrice comovement r=0.16 (1 year)SanofiRegeneron PharmaceuticalsPrice comovement r=0.09 (1 year)ExelixisPrice comovement r=0.03 (1 year)SeagenAbbViePrice comovement r=0.16 (1 year)Johnson & JohnsonPrice comovement r=0.05 (1 year)
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy